Ausgabe 3/2018
Inhalt (23 Artikel)
Is the whole larger than the sum of the parts? Integrated PET/MRI as a tool for response prediction
Felix M. Mottaghy
Integrated 18F-FDG PET/MRI in breast cancer: early prediction of response to neoadjuvant chemotherapy
Nariya Cho, Seock-Ah Im, Gi Jeong Cheon, In-Ae Park, Kyung-Hun Lee, Tae-Yong Kim, Young Seon Kim, Bo Ra Kwon, Jung Min Lee, Hoon Young Suh, Koung Jin Suh
Simultaneous whole-body 18F–PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study
Martin T. Freitag, Claudia Kesch, Jens Cardinale, Paul Flechsig, Ralf Floca, Matthias Eiber, David Bonekamp, Jan P. Radtke, Clemens Kratochwil, Klaus Kopka, Markus Hohenfellner, Albrecht Stenzinger, Heinz-Peter Schlemmer, Uwe Haberkorn, Frederik Giesel
Prognostic value of 18F–choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide
Paola Caroli, Ugo De Giorgi, Emanuela Scarpi, Lorenzo Fantini, Andrea Moretti, Riccardo Galassi, Monica Celli, Vincenza Conteduca, Lorena Rossi, Emanuela Bianchi, Giovanni Paganelli, Federica Matteucci
Prospective evaluation of 18F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate- to high-risk prostate cancer patients (FLUCIPRO trial)
Ivan Jambor, Anna Kuisma, Esa Kähkönen, Jukka Kemppainen, Harri Merisaari, Olli Eskola, Jarmo Teuho, Ileana Montoya Perez, Marko Pesola, Hannu J. Aronen, Peter J. Boström, Pekka Taimen, Heikki Minn
FDG PET/CT radiomics for predicting the outcome of locally advanced rectal cancer
Pierre Lovinfosse, Marc Polus, Daniel Van Daele, Philippe Martinive, Frédéric Daenen, Mathieu Hatt, Dimitris Visvikis, Benjamin Koopmansch, Frédéric Lambert, Carla Coimbra, Laurence Seidel, Adelin Albert, Philippe Delvenne, Roland Hustinx
Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab
Hoda Anwar, Christos Sachpekidis, Julia Winkler, Annette Kopp-Schneider, Uwe Haberkorn, Jessica C. Hassel, Antonia Dimitrakopoulou-Strauss
18F–fluorodeoxyglucose uptake of hepatocellular carcinoma as a prognostic predictor in patients with sorafenib treatment
Pil Soo Sung, Hye Lim Park, Keungmo Yang, Seawon Hwang, Myeong Jun Song, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Ie Ryung Yoo, Si Hyun Bae
Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinoma
Xavier Palard, Julien Edeline, Yan Rolland, Samuel Le Sourd, Marc Pracht, Sophie Laffont, Laurence Lenoir, Karim Boudjema, Thomas Ugen, Vanessa Brun, Habiba Mesbah, Laure-Anne Haumont, Pascal Loyer, Etienne Garin
Immunohistochemical evaluation of molecular radiotherapy target expression in neuroblastoma tissue
Jennifer E. Gains, Neil J. Sebire, Veronica Moroz, Keith Wheatley, Mark N. Gaze
EANM/EARL FDG-PET/CT accreditation - summary results from the first 200 accredited imaging systems
Andres Kaalep, Terez Sera, Wim Oyen, Bernd J. Krause, Arturo Chiti, Yan Liu, Ronald Boellaard
Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson’s disease
Han Soo Yoo, Seok Jong Chung, Su Jin Chung, Hyojeong Moon, Jung Su Oh, Jae Seung Kim, Jin Yong Hong, Byoung Seok Ye, Young Ho Sohn, Phil Hyu Lee
Head to head comparison of [18F] AV-1451 and [18F] THK5351 for tau imaging in Alzheimer’s disease and frontotemporal dementia
Young Kyoung Jang, Chul Hyoung Lyoo, Seongbeom Park, Seung Jun Oh, Hanna Cho, Minyoung Oh, Young Hoon Ryu, Jae Yong Choi, Gil D. Rabinovici, Hee Jin Kim, Seung Hwan Moon, Hyemin Jang, Jin San Lee, William J. Jagust, Duk L. Na, Jae Seung Kim, Sang Won Seo
Static and dynamic 18F–FET PET for the characterization of gliomas defined by IDH and 1p/19q status
Antoine Verger, Gabriele Stoffels, Elena K. Bauer, Philipp Lohmann, Tobias Blau, Gereon R. Fink, Bernd Neumaier, Nadim J. Shah, Karl-Josef Langen, Norbert Galldiks
Visualization of multiple organ amyloid involvement in systemic amyloidosis using 11C-PiB PET imaging
Naoki Ezawa, Nagaaki Katoh, Kazuhiro Oguchi, Tsuneaki Yoshinaga, Masahide Yazaki, Yoshiki Sekijima
Clinical utility of FDG PET/CT in acute complicated pyelonephritis—results from an observational study
Chih-Hsing Wan, Jing-Ren Tseng, Ming-Hsun Lee, Lan-Yan Yang, Tzu-Chen Yen
Current status of theranostics in prostate cancer
Irene Virgolini, Clemens Decristoforo, Alexander Haug, Stefano Fanti, Christian Uprimny
Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review
Finn Edler von Eyben, Giandomenico Roviello, Timo Kiljunen, Christian Uprimny, Irene Virgolini, Kalevi Kairemo, Timo Joensuu
Incidental identification of osteoid osteoma by 68Ga-PSMA PET/CT
Angelo Castello, Egesta Lopci
Striking lack of visualization of striatum on 18F-FDG brain PET in chorea-acanthocytosis
Diego Alfonso López-Mora, Valle Camacho, Alejandro Fernández, Esther Granell, Ignasi Carrió
177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?
Kambiz Rahbar, Hojjat Ahmadzadehfar, Martin Boegemann
Reply to ‘Single high dose versus repeated bone-targeted radionuclide therapy’
Ana M. Denis-Bacelar, Sarah J. Chittenden, David P. Dearnaley, Antigoni Divoli, Joe M. O’Sullivan, V. Ralph McCready, Bernadette Johnson, Yong Du, Glenn D. Flux